Does the FDA’s ‘breakthrough’ drug program need to be reformed? Harvard skeptics say yes
Of all the expedited review programs that the FDA has set up, none are as popular as the “breakthrough” therapy designation. And a group of …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.
